News & Events about Century Therapeutics Inc.
Latest Ratings for IPSC
DateFirmActionFromTo Nov 2021SVB LeerinkMaintainsOutperform Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021SVB LeerinkInitiates Coverage OnOutperform
View More Analyst Ratings for IPSC
View the Latest Analyst Ratings
read more...
Globe Newswire
7 months ago
Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer Michael C. Diem, M.D., promoted to Chief Financial Officer Hy Levitsky, M.D., rejoins as President of ...
Century Therapeutics, Inc. (NASDAQ:IPSC Get Rating) insider Luis Borges sold 63,616 shares of the firms stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the transaction, the ...
Ticker Report
8 months ago
Century Therapeutics, Inc. (NASDAQ:IPSC Get Rating) insider Luis Borges sold 63,616 shares of the firms stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the ...
Globe Newswire
8 months ago
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC...